Almujtama Alraida Medical Co. posted SAR 11.3 million net profit for the first half of 2023, an increase of 66% from SAR 6.8 million in H1 2022.
Item | 6m 2022 | 6m 2023 | Change |
---|---|---|---|
Revenues | 171.80 | 204.13 | 18.8 % |
Gross Income | 53.51 | 66.69 | 24.6 % |
Operating Income | 9.51 | 13.16 | 38.4 % |
Net Income | 6.84 | 11.33 | 65.7 % |
Average Shares | 9.50 | 9.50 | - |
EPS (Riyals) | 0.72 | 1.19 | 65.7 % |
Item | H1 2022 | H1 2023 | Change |
---|---|---|---|
Revenues | 171.80 | 204.13 | 18.8 % |
Gross Income | 53.51 | 66.69 | 24.6 % |
Operating Income | 9.51 | 13.16 | 38.4 % |
Net Income | 6.84 | 11.33 | 65.7 % |
Average Shares | 9.50 | 9.50 | - |
EPS (Riyals) | 0.72 | 1.19 | 65.7 % |
Item | H2 2022 | H1 2023 | Change |
---|---|---|---|
Revenues | 195.27 | 204.13 | 4.5 % |
Gross Income | 65.21 | 66.69 | 2.3 % |
Operating Income | 14.59 | 13.16 | (9.8 %) |
Net Income | 12.24 | 11.33 | (7.4 %) |
Average Shares | 9.50 | 9.50 | - |
EPS (Riyals) | 1.29 | 1.19 | (7.4 %) |
The profit increase came as sales rose 19% year-on-year (YoY) to SAR 204.1 million and gross profit margins increased to 33% from 31% in the prior-year period. Operating profit margin was stable YoY at 6%, while financing expenses declined.
Meanwhile, Zakat expenses surged 73% in H1 2023.
Shareholders' equity (with no minority interest) amounted to SAR 129.6 million in H1 2023, compared to SAR 105.7 million in H1 2022.
Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
---|---|---|---|---|---|---|
H1 2014 | - | - | - | - | - | - |
H2 2014 | - | - | - | - | - | - |
2014 | - | - | - | - | - | - |
H1 2015 | - | - | - | - | - | - |
H2 2015 | - | - | - | - | - | - |
2015 | - | - | - | - | - | - |
H1 2016 | - | - | - | - | - | - |
H2 2016 | - | - | - | - | - | - |
2016 | - | - | - | - | - | - |
H1 2017 | - | - | - | - | - | - |
H2 2017 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - |
H1 2018 | - | - | - | - | - | - |
H2 2018 | - | - | - | - | - | - |
2018 | - | - | - | - | - | - |
H1 2019 | - | - | - | - | - | - |
H2 2019 | - | - | - | - | - | - |
2019 | - | - | - | - | - | - |
H1 2020 | - | - | - | - | - | - |
H2 2020 | - | - | - | - | - | - |
2020 | - | - | - | - | - | - |
H1 2021 | - | - | - | - | - | - |
H2 2021 | - | - | - | - | - | - |
2021 | 304.50 | - | 85.38 | - | 8.59 | - |
H1 2022 | 171.80 | - | 53.51 | - | 9.51 | - |
H2 2022 | 195.27 | - | 65.21 | - | 14.59 | - |
2022 | 367.08 | 20.6 % | 118.71 | 39.0 % | 24.10 | 180.4 % |
H1 2023 | 204.13 | 18.8 % | 66.69 | 24.6 % | 13.16 | 38.4 % |
Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
---|---|---|---|---|---|---|
2013 | - | - | - | - | - | - |
2014 | - | - | - | - | - | - |
2015 | - | - | - | - | - | - |
2016 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - |
2018 | - | - | - | - | - | - |
2019 | - | - | - | - | - | - |
2020 | - | - | - | - | - | - |
2021 | 304.50 | - | 85.38 | - | 8.59 | - |
2022 | 367.08 | 20.6 % | 118.71 | 39.0 % | 24.10 | 180.4 % |
Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS Before XO Items |
---|---|---|---|---|---|---|
H1 2014 | - | - | - | - | - | - |
H2 2014 | - | - | - | - | - | - |
2014 | - | - | - | - | - | - |
H1 2015 | - | - | - | - | - | - |
H2 2015 | - | - | - | - | - | - |
2015 | - | - | - | - | - | - |
H1 2016 | - | - | - | - | - | - |
H2 2016 | - | - | - | - | - | - |
2016 | - | - | - | - | - | - |
H1 2017 | - | - | - | - | - | - |
H2 2017 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - |
H1 2018 | - | - | - | - | - | - |
H2 2018 | - | - | - | - | - | - |
2018 | - | - | - | - | - | - |
H1 2019 | - | - | - | - | - | - |
H2 2019 | - | - | - | - | - | - |
2019 | - | - | - | - | - | - |
H1 2020 | - | - | - | - | - | - |
H2 2020 | - | - | - | - | - | - |
2020 | - | - | - | - | - | - |
H1 2021 | - | - | - | - | - | - |
H2 2021 | - | - | - | - | - | - |
2021 | 7.81 | - | 11.08 | - | 7.81 | 11.08 |
H1 2022 | 6.84 | - | 0.72 | - | 6.84 | 0.72 |
H2 2022 | 12.24 | - | 1.29 | - | 12.24 | 1.29 |
2022 | 19.08 | 144.3 % | 2.01 | - | 19.08 | 2.01 |
H1 2023 | 11.33 | 65.7 % | 1.19 | - | 11.33 | 1.19 |
Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS Before XO Items |
---|---|---|---|---|---|---|
2013 | - | - | - | - | - | - |
2014 | - | - | - | - | - | - |
2015 | - | - | - | - | - | - |
2016 | - | - | - | - | - | - |
2017 | - | - | - | - | - | - |
2018 | - | - | - | - | - | - |
2019 | - | - | - | - | - | - |
2020 | - | - | - | - | - | - |
2021 | 7.81 | - | 11.08 | - | 7.81 | 11.08 |
2022 | 19.08 | 144.3 % | 2.01 | - | 19.08 | 2.01 |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
H1 2014 | - | - | - |
H2 2014 | - | - | - |
2014 | - | - | - |
H1 2015 | - | - | - |
H2 2015 | - | - | - |
2015 | - | - | - |
H1 2016 | - | - | - |
H2 2016 | - | - | - |
2016 | - | - | - |
H1 2017 | - | - | - |
H2 2017 | - | - | - |
2017 | - | - | - |
H1 2018 | - | - | - |
H2 2018 | - | - | - |
2018 | - | - | - |
H1 2019 | - | - | - |
H2 2019 | - | - | - |
2019 | - | - | - |
H1 2020 | - | - | - |
H2 2020 | - | - | - |
2020 | - | - | - |
H1 2021 | - | - | - |
H2 2021 | - | - | - |
2021 | 28.04 % | 10.63 % | 2.56 % |
H1 2022 | - | - | - |
H2 2022 | 32.34 % | 12.57 % | 5.20 % |
2022 | 32.34 % | 12.57 % | 5.20 % |
H1 2023 | 33.02 % | 13.38 % | 5.90 % |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
2013 | - | - | - |
2014 | - | - | - |
2015 | - | - | - |
2016 | - | - | - |
2017 | - | - | - |
2018 | - | - | - |
2019 | - | - | - |
2020 | - | - | - |
2021 | 28.04 % | 10.63 % | 2.56 % |
2022 | 32.34 % | 12.57 % | 5.20 % |
Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
---|---|---|---|
H1 2014 | - | - | - |
H2 2014 | - | - | - |
H1 2015 | - | - | - |
H2 2015 | - | - | - |
H1 2016 | - | - | - |
H2 2016 | - | - | - |
H1 2017 | - | - | - |
H2 2017 | - | - | - |
H1 2018 | - | - | - |
H2 2018 | - | - | - |
H1 2019 | - | - | - |
H2 2019 | - | - | - |
H1 2020 | - | - | - |
H2 2020 | - | - | - |
H1 2021 | - | - | - |
H2 2021 | - | - | - |
H1 2022 | 31.14 % | 11.36 % | 3.98 % |
H2 2022 | 33.39 % | 13.63 % | 6.27 % |
H1 2023 | 32.67 % | 13.13 % | 5.55 % |
Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
---|---|---|---|---|
H1 2014 | - | - | - | - |
H2 2014 | - | - | - | - |
H1 2015 | - | - | - | - |
H2 2015 | - | - | - | - |
H1 2016 | - | - | - | - |
H2 2016 | - | - | - | - |
H1 2017 | - | - | - | - |
H2 2017 | - | - | - | - |
H1 2018 | - | - | - | - |
H2 2018 | - | - | - | - |
H1 2019 | - | - | - | - |
H2 2019 | - | - | - | - |
H1 2020 | - | - | - | - |
H2 2020 | - | - | - | - |
H1 2021 | - | - | - | - |
H2 2021 | - | - | - | - |
H1 2022 | 9.50 | - | - | 11.12 |
H2 2022 | 9.50 | 2.01 | 2.01 | 12.48 |
H1 2023 | 9.50 | 2.48 | 2.48 | 13.65 |
Period | Shares Outstanding (M) | EPS (Riyal) | Adjusted EPS (Riyal) | Book Value (BV) |
---|---|---|---|---|
2013 | - | - | - | - |
2014 | - | - | - | - |
2015 | - | - | - | - |
2016 | - | - | - | - |
2017 | - | - | - | - |
2018 | - | - | - | - |
2019 | - | - | - | - |
2020 | - | - | - | - |
2021 | 0.71 | 11.08 | 11.08 | 12.34 |
2022 | 9.50 | 2.01 | 2.01 | 12.48 |
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
H1 2014 | - | - | - |
H2 2014 | - | - | - |
H1 2015 | - | - | - |
H2 2015 | - | - | - |
H1 2016 | - | - | - |
H2 2016 | - | - | - |
H1 2017 | - | - | - |
H2 2017 | - | - | - |
H1 2018 | - | - | - |
H2 2018 | - | - | - |
H1 2019 | - | - | - |
H2 2019 | - | - | - |
H1 2020 | - | - | - |
H2 2020 | - | - | - |
H1 2021 | - | - | - |
H2 2021 | - | - | - |
H1 2022 | - | - | - |
H2 2022 | - | - | - |
H1 2023 | - | - | - |
Period | P/E | Adjusted P/E | Price/book |
---|---|---|---|
2013 | - | - | - |
2014 | - | - | - |
2015 | - | - | - |
2016 | - | - | - |
2017 | - | - | - |
2018 | - | - | - |
2019 | - | - | - |
2020 | - | - | - |
2021 | - | - | - |
2022 | - | - | - |
Q2 2023
2023
Period | Pharmaceutical products | Personal care products | Mother and baby care products | Nutritional supplements | Medical tools and devices |
---|---|---|---|---|---|
Q2 2023 | 130.28 | 35.29 | 19.22 | 14.45 | 4.89 |
Period | Pharmaceutical products | Personal care products | Mother and baby care products | Nutritional supplements | Medical tools and devices |
---|---|---|---|---|---|
2022 | 227.67 | 68.93 | 38.84 | 25.58 | 6.06 |
Current | |
Market Cap (M Riyal) | 291.18 |
Enterprise Value (EV) (M) | 278.18 |
Shares Outstanding ((M)) | 9.50 |
Book Value (BV) ( Riyal) | 13.66 |
Par Value ( Riyal) | 10.00 |
Adjusted P/E (Last12) | 25.56 |
Price/book | 2.24 |
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments {{getCommentCount()}}
Be the first to comment
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}